ホーム
探索
nav.journalClub
トレンド
その他
synapse
⌘+K
言語
日本語
日本語
Donor Lymphocyte Infusion in Myeloid Malignancies: Reassessing Predictors of Response | Synapse
March 3, 2026
Donor Lymphocyte Infusion in Myeloid Malignancies: Reassessing Predictors of Response
AF
Allison Fungsoph
OR
Olivia R. S. Rogers
Fred Hutch Cancer Center
LL
Lucas Liu
See all
Key Points
Response to donor lymphocyte infusion varies based on specific predictors observed in myeloid malignancies.
Key findings reveal that certain factors significantly correlate with treatment effectiveness, guiding future interventions.
Analysis of clinical data highlights the role of immunotherapy in enhancing responses after donor lymphocyte infusion.
These insights may enable personalized approaches in treating myeloid malignancies, optimizing donor lymphocyte use.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Fungsoph et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76003c6e9836116a2c6a2
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.567